
Monash IVF flags FY27 profit below $16.1M
Key points
- Monash IVF Group stated that its FY27 underlying net profit after tax is expected to fall materially below FY26 and analyst estimates.
- The company’s share price dropped 20.67% to $0.60 following the trading update.
- The company is executing a productivity programme targeting $8–$11 million in annualised pre-tax savings to offset rising costs and slower cycle volumes.
Monash IVF Group (ASX:MVF) announced that its FY27 underlying net profit after tax is expected to fall materially below FY26 and consensus estimates, as Australian stimulated-cycle volumes contracted 3.2% in Q1 FY27.
The earnings downgrade follows FY26's underlying net profit after tax of $16.1 million, which had already fallen 41.2% compared to FY25.
"MVF has a strong clinical and scientific platform, and the long-term drivers of demand for fertility care remain compelling," said Monash IVF Group Chair Catherine West.
The company reported that its productivity programme targets $8–$11 million in annualised pre-tax savings, though benefits are expected to realise more slowly than previously anticipated.
Monash IVF stated that it will provide a further trading update when it releases its half-year financial results.
Following the announcement, the Monash IVF Group share price was down at $0.60.
In August, the company launched its Nurture 2030 three-year strategy to cut capital expenditure by 50% and rebuild organic growth.
Recent company moves include appointing Matt Harrington as CFO in October, refreshing its board in August, and expanding its debt facility to $130 million.
